霍奇金淋巴瘤放疗后乳腺癌风险:性腺激素暴露的影响
该巢式病例对照研究纳入174例乳腺癌患者和466例对照,评估女性霍奇金淋巴瘤5年生存者胸部放疗后乳腺癌风险与性腺激素暴露的关系。结果显示乳腺癌风险随乳腺放疗剂量线性增加,调整后超额比值比为6.1%/Gy(95%CI 2.1%-15.4%);早绝经者乳腺癌风险较低,放疗后卵巢功能保留时间每增加1年风险增加6.4%(P<.001);早绝经者使用激素替代治疗≥2年未增加乳腺癌风险。
要点
- 乳腺癌风险随乳腺放疗剂量线性增加,调整后EOR为6.1%/Gy(95%CI 2.1%-15.4%)。
- 早绝经(<30岁)者乳腺癌风险低于≥50岁绝经者(OR 0.13,95%CI 0.03-0.51)。
- 放疗后卵巢功能保留每多1年,乳腺癌风险增加6.4%(P<.001)。
核心结论
- 女性霍奇金淋巴瘤生存者乳腺癌风险随乳腺放疗剂量线性增加。
- 激素替代治疗似乎不增加治疗所致早绝经者的乳腺癌风险。
- 内源性和外源性性腺激素未显示影响放疗剂量-反应关系。
研究设计与样本
- 巢式病例对照研究,纳入174例乳腺癌患者和466例对照。
- 对象为41岁前接受治疗且生存5年的女性霍奇金淋巴瘤患者。
- 激素暴露和治疗数据来自病历和问卷,乳腺剂量基于放疗图表、模拟片和钼靶报告估算。
主要发现
- 调整后超额比值比为6.1%/Gy(95%CI 2.1%-15.4%)。
- 早绝经(<30岁,由高剂量丙卡巴肼或盆腔放疗导致)者乳腺癌风险低于≥50岁绝经者(OR 0.13,95%CI 0.03-0.51)。
- 放疗后卵巢功能保留每增加1年,乳腺癌风险增加6.4%(P<.001)。
- 早绝经(<45岁)者激素替代治疗≥2年未增加乳腺癌风险(OR 0.86,95%CI 0.32-2.32)。
- 无早绝经者激素替代治疗风险非显著增加(OR 3.69,95%CI 0.97-14.0;交互作用P=.06)。
关键数值与推荐
- 按放疗后卵巢功能保留时间或激素替代治疗使用时长分层未显著改变放疗剂量-反应曲线。
临床怎么用
- 对霍奇金淋巴瘤胸部放疗生存者应关注乳腺癌风险,风险随放疗剂量线性增加。
- 治疗所致早绝经者使用激素替代治疗≥2年未显示增加乳腺癌风险。
- 内源性和外源性性腺激素未显示影响放疗剂量-反应关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Young women treated with chest radiation therapy (RT) for Hodgkin lymphoma (HL) experience a strongly increased risk of breast cancer (BC). It is unknown whether endogenous and exogenous gonadal hormones affect RT-associated BC risk. METHODS: We conducted a nested case-control study among female 5-year HL survivors treated before age 41. Hormone exposure and HL treatment data were collected through medical records and questionnaires for 174 BC case patients and 466 control patients. Radiation dose to breast tumor location was estimated based on RT charts, simulation films, and mammography reports. RESULTS: We observed a linear radiation dose-response curve with an adjusted excess odds ratio (EOR) of 6.1%/Gy (95% confidence interval [CI]: 2.1%-15.4%). Women with menopause <30 years (caused by high-dose procarbazine or pelvic RT) had a lower BC risk (OR, 0.13; 95% CI, 0.03-0.51) than did women with menopause ≥50 years. BC risk increased by 6.4% per additional year of post-RT intact ovarian function (P<.001). Among women with early menopause (<45 years), hormone replacement therapy (HRT) use for ≥2 years did not increase BC risk (OR, 0.86; 95% CI, 0.32-2.32), whereas this risk was nonsignificantly increased among women without early menopause (OR, 3.69; 95% CI, 0.97-14.0; P for interaction: .06). Stratification by duration of post-RT intact ovarian function or HRT use did not statistically significantly modify the radiation dose-response curve. CONCLUSIONS: BC risk in female HL survivors increases linearly with radiation dose. HRT does not appear to increase BC risk for HL survivors with therapy-induced early menopause. There are no indications that endogenous and exogenous gonadal hormones affect the radiation dose-response relationship.
引用
- Krul IM, Opstal-van Winden AWJ, Aleman BMP, et al. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. Int J Radiat Oncol Biol Phys. 2017. PMID: 28888722. doi:10.1016/j.ijrobp.2017.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。